Primecap Management Co. CA Sells 2,290 Shares of Charles River Laboratories International, Inc. $CRL

Primecap Management Co. CA lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% during the 2nd quarter, HoldingsChannel reports. The firm owned 270,600 shares of the medical research company’s stock after selling 2,290 shares during the period. Primecap Management Co. CA’s holdings in Charles River Laboratories International were worth $41,058,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group grew its position in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC grew its holdings in shares of Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares in the last quarter. Allworth Financial LP increased its position in shares of Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 190 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at about $56,000. Finally, Bayforest Capital Ltd bought a new stake in Charles River Laboratories International during the second quarter worth about $63,000. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Morgan Stanley upped their price target on shares of Charles River Laboratories International from $170.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Argus set a $200.00 price target on shares of Charles River Laboratories International in a research note on Monday. Mizuho boosted their price objective on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Finally, Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price target for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $190.86.

Charles River Laboratories International Trading Down 0.5%

Shares of NYSE CRL opened at $161.65 on Thursday. The stock has a market cap of $7.96 billion, a P/E ratio of -121.54, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $203.01. The firm has a 50 day moving average price of $169.04 and a two-hundred day moving average price of $158.23.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. During the same period in the prior year, the business posted $2.59 earnings per share. The firm’s revenue was down .5% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).